Secondary Schizophrenia (170 page)

Kristensen, K.,
90

hallucinosis,
198

infantile,
328

organic in,
18

Kufs’ Disease,
215t
,
219–
20,
222

psychosis,
113

Kumral, E.,
198,
199

IBGC. Se
e Fahr’s Disease (IBGC) and

substance-induced psychosis,
113

kyphoscoliosis,
333

psychosis

Lahti, A. C.,
146

L’Hermitte, J.,
26,
198,
200

laterality of epileptic focus,
91

lamotrigine,
87,
155

Libon, D. J.,
207

leukodystrophies,
242–
3,
248,
249

mesial temporal structures,
109

Landolt, H.,
87,
103–
4

Lieberman, J. A.,
118

mitochondrial disorders and

late development model, in

Lifetime Dimensions of Psychosis

psychosis,
233–
4,
235

schizophrenia,
9

Scale (LDPS),
289

multiple sclerosis,
276–
7

postictal psychosis,
84

latent class analysis (LCA),
289

ligand binding,
66–
7

psychotic patient with epilepsy,
92

lateralizing dysgraphesthesia,
53

limbic kindling,
93,
105–
6

structural (volumetric)

intercorrelations,
63

Laurelle, M.,
134

Linszen, D. H.,
174,
175

tinnitus study,
29

Lauter, H.,
204

lipid storage disorders,
214–
15, 215t

Wilson’s Disease,
339

Lauterbach, E. C.,
358

Lisanby, S.,
264

magnetic resonance spectroscopy

Lavan, J.,
180

Lishman, W.,
190

(MRS),
7

1H (Proton) MRS,
7

LD Mapping,
290,
291,
297

Liu, Y. L.,
294

Niemann-Pick Disease type C,

Leber hereditary optic neuropathy

Livermore, A.,
105–
6

217–
18

(LHON),
232

Logsdail, S. J.,
83,
84

magnetoencephalography (MEG)

Lee, K. H.,
65

epilepsy,
83,
96

long-term potentiation (LTP),
106

tinnitus,
29

Leigh Syndrome,
230

lorazepam,
277

major depressive disorder,
293

Lennox, W. G.,
33

Lorenzo’s oil,
244

leukodystrophies, psychosis associated

Malamud, N.,
265

Lowenthal, A.,
359

with

Malaspina, D.,
188,
192

adrenoleukodystrophy,
220–
1,
243

low-resolution electromagnetic

Malhotra, A. K.,
146

diagnostic tests,
244

tomography (LORETA),
65

genetics and pathobiology,
243

Luby, E. D.,
144

Maneros, M.,
382

neurological features/endocrine

mania,
258

abnormalities,
244

Luisada, P. V.,
143

and brain tumor,
266

prevalence,
244

Luria, A.,
50

and Fahr’s Disease,
360

psychiatric features,
244,
245t

LY354740,
155

and Huntington’s Disease,
349

treatment,
243,
244

treatment,
396–
7

Alexander’s Disease,
249

Lyketsos, C. G.,
200,
205–
7

cerebrotendinous xanthomatosis,

Manyam, B. V.,
360

lysergic acid diethylamide (LSD)

218–
19,
248–
9

illicit use of,
147

marijuana. See
cannabis

clinical features,
242–
3

psychotomimetic effects,
147–
8

age at onset/cause of illness,
242

Martinez-Arevalo, M. J.,
174

visual hallucinations and,
27,
121,

neurological features,
242

147–
8

maternal genital/reproductive (GR)

psychiatric features,
242

infections,
282

diagnosis,
243

lysosomal storage disorders,
214–
15,

maternally inherited Leigh Syndrome

future research,
250

215t
,
216

(MILS),
232

genetics and pathobiology,
242

Krabbe’s Disease,
248

MacQueen, G.,
216

Mathern, G. W.,
84

management,
249

magnetic gait,
51

Mauguiere, F.,
30

membranous lipodystrophy,
249

metachromatic leukodystrophy,
241

magnetic resonance imaging (MRI)

McHugh, P. R.,
351

neuroimaging,
242–
3,
244

adult with VCFS,
315–
16

MDMA. See
Ecstasy

overview,
241

brain tumor,
266

medial temporal lobes, volume

Pelizaeus-Merzbacher Disease,
248

brain volume reductions/increases

reductions in,
6

prevalence,
242

study,
6

psychiatric illness treatment,

cerebrovascular disease,
201

medication adherence,
413

249–
50

childhood-onset schizophrenia

study,
6–
7

medicolegal practice, and traumatic

leutinizing hormone,
328

child with VCFS,
314–
15

brain injury,
193–
4

levetiracetam,
87

epilepsy,
96

mediobasal epilepsy,
90

Fahr’s Disease,
361

Levine, D. N.,
200

megalencephaly,
249

Friedrich’s Ataxia,
334

Lewy-Body dementia (LBD),
27,
396

Huntington’s Disease,
350

MELAS,
231–
2,
233,
234,
235

membrane phospholipids (MPLs),
7–
8

schizophrenia-like psychosis,
232–
8

Nakatani, Y.,
128,
130

membranous lipodystrophy,
249

coenzyme Q role,
233,
235

Nasrallah, H.,
187,
193

conclusions,
236–
8

Mendez, M. F.,
89,
90

family history,
235–
6

National Cancer Institute – National

mental retardation,
81,
218,
249,
310,

onset age,
234–
5

Human Genome Research

311,
333,
397

psychotic symptom overview,

Institute (NCI-NHGRI)

237t

Working Group on

mesial sclerosis,
94

symptoms related to delirium or

Replication in Association,

mesolimbic dopamine system,

dementia,
235

298

118–
19

Wolfram Disease,
236

National Institutes of Mental

metachromatic leukodystrophy

mitochondrial encephalomyopathy,

Health-Measurement and

(MLD),
53,
220,
241

lactic acidosis, stroke-like

Treatment Research to

episodes syndrome

Improve Cognition in

Met allele,
317–
18

(MELAS),
231–
2,
233,
234,

Schizophrenia

methamphetamine (MA)

235,
383

(NIMH-MATRICS),
312

epidemiology of,
128–
9

Mitsuda, H.,
382

National Survey of Mental Health and

and psychosis,
130,
131

Wellbeing (NSMHWB),
170

mixed mania,
396–
7

micro RNA studies,
297

N-back task,
5

Mizukami, K.,
233

migraine, and hallucinations,
33

Ndetei, D. M.,
32

MK-801,
87

Millar, J. K.,
296

negative gustatory hallucinations,

Moghaddam, B.,
150–
1,
152–
3

Miller, H.,
189–
90

33–
4

molecular genetics,
290

minocycline,
353

negative symptoms, of schizophrenia,

molindone,
87

3–
4

misattribution of speech,
66

Monroe, R.,
382

Negrete, J. C.,
174

mismatch negativity (MMN),
132,
147

mood disorder

neocortical temporal lobe epilepsy,
90

mitochondrial encephalopathy,
81

hallucinations in,
22

nerve growth factor (NGF),
107

mitochondrial neurogastrointestinal

and Huntington’s Disease,
349

encephalomyopathy,
230

psychotic,
117

neural developmental theory of

schizophrenia,
309

mitochondrial disorders

and schizophrenia,
393

clinical consequences,
230–
1, 231t

treatm
ent,
396
See also affective

neurochemical brain imaging,
7–
8

due to mitochondrial genome

disorder

magnetic resonance spectroscopy,
7

mutations,
231

morphine,
370

positron emission tomography,
7

MELAS,
231–
2,
233,
234,
235

single photon emission computed

motivational interviewing,
407

Kearns-Sayre Syndrome,
232

tomography,
7

Leber hereditary optic

motor coordination,
49–
50

striatal Fluoro-DOPA uptake,
7

neuropathy,
232

motor inhibition deficits,
50

in vivo 31P spectroscopy,
7–
8

maternally inherited Leigh

neurodegenerative disorders. See

Syndrome,
232

motor sequencing tests,
50

Alzheimer’s Disease (AD);